SCHEMBL14807662

SCHEMBL14807662

Cc1ccc(C(=O)Nc2nc3ccc(C(=O)O)cc3s2)cc1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 1/20 0.70
HSD17B10 Q99714 1/20 0.67
NPC1 O15118 4/20 0.65
RAB9A P51151 4/20 0.65
ALDH1A1 P00352 4/20 0.65
KDM4E B2RXH2 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
TDP1 Q9NUW8 2/20 0.65
HPGD P15428 2/20 0.65
KLK7 P49862 1/20 0.65
SCD O00767 3/20 0.62
RXFP1 Q9HBX9 2/20 0.62
ATM Q13315 1/20 0.62
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
HTT P42858 1/20 0.61
LRRK2 Q5S007 2/20 0.60
LCK P06239 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24729341 0.92 HSD17B10 (0.73) MAP3K5HSD17B10NPC1RAB9AALDH1A1
SCHEMBL29947460 0.92 HSD17B10 (0.73) MAP3K5HSD17B10NPC1RAB9AALDH1A1
SCHEMBL13329390 0.91 MAP3K5 (0.83) MAP3K5HSD17B10NPC1RAB9AALDH1A1
SCHEMBL14807902 0.90 SMN1; SMN2 (0.74) MAP3K5NPC1RAB9AALDH1A1KDM4E
SCHEMBL14807050 0.88 HTT (0.79) MAP3K5NPC1RAB9AALDH1A1KDM4E
SCHEMBL14807016 0.87 SCD (0.77) MAP3K5NPC1RAB9AALDH1A1KDM4E
SCHEMBL12717675 0.87 NPC1 (0.81) MAP3K5HSD17B10NPC1RAB9AALDH1A1
SCHEMBL24729344 0.87 NPC1 (0.67) MAP3K5HSD17B10NPC1RAB9AALDH1A1
SCHEMBL13329360 0.87 HSD17B1 (0.74) MAP3K5NPC1RAB9AALDH1A1KDM4E
SCHEMBL24729458 0.86 HSD17B10 (0.63) MAP3K5HSD17B10NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150011528-A1 PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME YUHAN CORPORATION (KR) 2015-01-08 US disclosed
EP-2758384-A1 PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Yuhan Corporation (KR) 2014-07-30 EP disclosed
WO-2013043001-A1 PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME YUHAN CORPORATION (KR) 2013-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011528-A1 PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME ILK, PKMYT1, PLAUR MAP3K5 332/4885HSD17B10 3612/4885NPC1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.